What is AnaBios?
AnaBios operates at the forefront of translational medicine, leveraging advanced technologies to evaluate the safety and efficacy of new therapeutic compounds. The company's core mission is to tackle critical areas of unmet medical need, including cardiovascular conditions, pain management, and dermatological itch. By collaborating with Fortune 500 biotech entities, Contract Research Organizations (CROs), and academic institutions, AnaBios not only supports external drug development but also cultivates its own internal drug discovery platform through in-licensed programs from pharmaceutical partners. This dual approach positions AnaBios as a key player in accelerating the development of innovative treatments.
How much funding has AnaBios raised?
AnaBios has raised a total of $12.3M across 3 funding rounds:
Series A
$2M
Series B
$10M
Debt
$350K
Series A (2011): $2M with participation from Tech Coast Angels
Series B (2016): $10M led by Principia SGR
Debt (2020): $350K supported by PPP
Key Investors in AnaBios
Tech Coast Angels
Tech Coast Angels is a prominent angel investment group known for backing early-stage companies, particularly in the technology and life sciences sectors within Southern California.
Principia SGR
Principia SGR is an Italian venture capital firm with a dedicated focus on the healthcare sector, investing in start-up, early-stage, and growth-stage companies.
PPP
Public-Private Partnership
What's next for AnaBios?
With a foundation built on substantial enterprise-level backing and a clear strategic focus on high-impact therapeutic areas, AnaBios is poised for accelerated growth and innovation. The company's commitment to human-focused translational technologies suggests a trajectory aimed at advancing its internal drug discovery pipeline and expanding its collaborative efforts. Future developments are likely to center on clinical validation of its proprietary compounds and further strategic partnerships to broaden its market reach and therapeutic impact. The recent undisclosed funding, coupled with its history of securing significant capital, indicates a strong market appetite for AnaBios's unique approach to drug development and safety assessment.
See full AnaBios company page
